Analysts Set Savara Inc. (NASDAQ:SVRA) Target Price at $10.14

Savara Inc. (NASDAQ:SVRA) has been given an average recommendation of “Moderate Buy” by the eight ratings firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $10.1429.

A number of equities analysts have recently weighed in on SVRA shares. Oppenheimer began coverage on Savara in a research note on Friday, April 24th. They issued an “outperform” rating and a $11.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. Finally, Wall Street Zen raised Savara from a “sell” rating to a “hold” rating in a report on Saturday, June 13th.

Institutional Investors Weigh In On Savara

Several institutional investors and hedge funds have recently modified their holdings of SVRA. Swedbank AB increased its holdings in Savara by 54.5% in the 4th quarter. Swedbank AB now owns 850,000 shares of the company’s stock valued at $5,126,000 after acquiring an additional 300,000 shares during the last quarter. F m Investments LLC boosted its holdings in shares of Savara by 56.5% during the 4th quarter. F m Investments LLC now owns 678,813 shares of the company’s stock valued at $4,093,000 after purchasing an additional 245,100 shares during the last quarter. Nan Fung Trinity HK Ltd. purchased a new position in shares of Savara during the fourth quarter valued at about $10,182,000. Orbimed Advisors LLC purchased a new position in shares of Savara during the first quarter valued at about $3,467,000. Finally, Seven Fleet Capital Management LP grew its position in shares of Savara by 371.1% during the first quarter. Seven Fleet Capital Management LP now owns 295,688 shares of the company’s stock valued at $1,614,000 after purchasing an additional 232,926 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Savara Stock Up 1.8%

Shares of SVRA stock opened at $5.51 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.47 and a quick ratio of 13.47. Savara has a one year low of $2.43 and a one year high of $7.01. The company’s fifty day moving average price is $5.60 and its 200-day moving average price is $5.50. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -9.84 and a beta of 0.29.

Savara (NASDAQ:SVRA) last issued its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Sell-side analysts expect that Savara will post -0.57 EPS for the current fiscal year.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.